Gemcitabine is a deoxycytidine analogue that has a broad spectrum of antitumour activity in many solid tumours including pancreatic cancer. We have recently carried out a pharmacogenomic study in cancer patients treated with gemcitabine, and found that one genetic polymorphism of an enzyme involved in gemcitabine metabolism can cause interindividual variations in the pharmacokinetics and toxicity of this agent. In this paper, we review recent genetic studies of gemcitabine, and discuss the possibility of individualised cancer chemotherapy based on a pharmacogenomic approach.
机构:Evanston,Michael C. Jewett is in the Department of Chemical and Biological Engineering and the Center for Synthetic Biology at Northwestern University
Michael C. Jewett
Vincent Noireaux
论文数: 0引用数: 0
h-index: 0
机构:Evanston,Michael C. Jewett is in the Department of Chemical and Biological Engineering and the Center for Synthetic Biology at Northwestern University